|Bid||79.66 x 100|
|Ask||79.67 x 200|
|Day's Range||79.17 - 79.77|
|52 Week Range||73.69 - 89.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.25 (2.82%)|
|1y Target Est||N/A|
Wall Street analysts expect an ~3.0% increase in Eli Lilly & Co.’s (LLY) 1Q18 revenues to $5.5 billion. Eli Lilly’s products are sold in more than 120 countries, and its international sales comprise ~45.0% of its total revenues. As a result, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenues during 1Q18.
Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.
Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.
Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.
GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.
Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.